$5.36
4.86% today
Nasdaq, Dec 04, 08:47 pm CET
ISIN
US02155H1014
Symbol
ALT

Altimmune, Inc. Stock price

$5.11
+1.15 29.04% 1M
-0.31 5.72% 6M
-2.10 29.13% YTD
-3.68 41.87% 1Y
-5.95 53.80% 3Y
-7.72 60.17% 5Y
+3.15 160.48% 10Y
-3.01 37.06% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+0.35 7.35%
ISIN
US02155H1014
Symbol
ALT
Industry

Key metrics

Basic
Market capitalization
$533.2m
Enterprise Value
$336.9m
Net debt
positive
Cash
$210.8m
Shares outstanding
95.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
26,659.5 | 93,767.5
EV/Sales
16,843.0 | 59,240.6
EV/FCF
negative
P/B
2.9
Dividends
DPS
$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$20.0k | $5.7k
EBITDA
$-90.3m | $-99.6m
EBIT
$-90.5m | $-99.4m
Net Income
$-83.9m | $-107.3m
Free Cash Flow
$-66.4m
Growth (TTM | estimate)
Revenue
-60.0% | -71.5%
EBITDA
18.8% | 3.2%
EBIT
19.2% | 3.7%
Net Income
18.9% | -12.8%
Free Cash Flow
15.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-451,715.0% | -1,751,643.0%
EBIT
-452,310.0%
Net
-419,575.0% | -1,886,529.3%
Free Cash Flow
-331,810.0%
Financial Health
Equity Ratio
88.7%
Return on Equity
-77.0%
ROCE
-44.0%
ROIC
-
Debt/Equity
0.1
More
EPS
$-0.9
FCF per Share
$-0.7
Short interest
22.5%
Employees
59
Rev per Employee
$0.0
Show more

Is Altimmune, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Altimmune, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Altimmune, Inc. forecast:

11x Buy
79%
2x Hold
14%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a Altimmune, Inc. forecast:

Buy
79%
Hold
14%
Sell
7%

Financial data from Altimmune, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.02 0.02
60% 60%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
12% 12%
113,400%
- Research and Development Expense 68 68
15% 15%
339,000%
-90 -90
19% 19%
-451,700%
- Depreciation and Amortization 0.12 0.12
82% 82%
600%
EBIT (Operating Income) EBIT -90 -90
19% 19%
-452,310%
Net Profit -84 -84
19% 19%
-419,600%

In millions USD.

Don't miss a Thing! We will send you all news about Altimmune, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Altimmune, Inc. Stock News

Neutral
GlobeNewsWire
3 days ago
Altimmune announces CEO transition and succession plan under which Jerry Durso will assume the role of President and Chief Executive Officer on January 1.
Neutral
GlobeNewsWire
8 days ago
GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. Details are as follows:
Neutral
Seeking Alpha
14 days ago
Altimmune, Inc. ( ALT ) Jefferies London Healthcare Conference 2025 November 20, 2025 3:00 AM EST Company Participants Vipin Garg - President, CEO & Director Christophe Arbet-Engels - Chief Medical Officer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division All right. Good morning, everyone, to Jefferies' London Hea...
More Altimmune, Inc. News

Company Profile

Altimmune, Inc. is a clinical stage immunotherapeutic biotechnology company. It focuses on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. The company's portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. Altimmune was founded in 1997 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Vipin Garg
Employees 59
Founded 1997
Website altimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today